Shots:
- Genentech has reported the P-III trials results, incl. FENhance 2 study assessing fenebrutinib (PO) vs teriflunomide in 1,497 adults with RMS for ~96wks.
- Trial met its 1EP of reduced annualized relapse rate over ~96wks. with favorable liver safety; additional safety data will be further evaluated; data to be presented in future meeting, along with P-III (FENhance 1) trial data (expected in H1’26)
- Additionally, the P-III (FENtrepid) trial in PPMS also met its 1EP, showing fenebrutinib’s non-inferiority to Ocrevus in delaying confirmed disability progression over 120wks., with numerical benefits seen as early as Wk. 24 & sustained throughout the study period
Ref: Genentech| Image: Genentech| Press Release
Related News:- Genentech Reports P-III (ALLEGORY) Trial Findings on Gazyva (Obinutuzumab) for Systemic Lupus Erythematosus (SLE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
